Related Experiment Videos
Kawasaki syndrome
1Department of Pediatrics, Harvard Medical School, Boston, Massachusetts.
Insights
Kawasaki syndrome can cause pediatric heart disease, but early treatment with intravenous gamma globulin significantly reduces coronary artery aneurysm risk. Long-term monitoring is crucial for all patients to track heart and valve health.
Area of Science:
- Pediatric Cardiology
- Immunology
- Vascular Biology
Background:
- Kawasaki syndrome is a primary cause of acquired pediatric heart disease in the US.
- Coronary artery aneurysms affect 15-25% of children with Kawasaki syndrome.
- Intravenous gamma globulin (IVIG) treatment in acute Kawasaki syndrome reduces aneurysm risk 3-5 fold.
Purpose of the Study:
- To review the long-term sequelae of Kawasaki syndrome.
- To assess the impact on coronary artery status, myocardial function, and valvar regurgitation.
- To highlight the need for continued surveillance in affected children.
Main Methods:
- Review of existing literature on Kawasaki syndrome outcomes.
- Analysis of angiographic, histologic, and functional data.
- Evaluation of myocardial and valvar function in patients with and without coronary artery disease.
Main Results:
- Half of aneurysmal coronary segments resolve angiographically but retain histologic/functional deficits.
- Remaining aneurysms may progress to stenosis or occlusion.
- Myocarditis is universal in acute Kawasaki syndrome; late myocardial dysfunction is debated, especially without coronary artery disease.
- Aortic and mitral regurgitation can occur acutely, with rare late-onset complications.
Conclusions:
- Long-term surveillance is essential for Kawasaki syndrome patients.
- Monitoring should encompass coronary artery status, myocardial function, and valvar regurgitation.
- Understanding the natural history informs management and predicts long-term outcomes.
Abstract:
Kawasaki syndrome is a leading cause of pediatric acquired heart disease in the United States. Coronary artery aneurysms or ectasia develop in approximately 15 to 25 per cent of affected children; treatment with intravenous gamma globulin in the acute phase reduces this risk three- to five-fold. Angiographic resolution occurs in approximately one half of aneurysmal arterial segments, but these show persistent histologic and functional abnormalities. The remainder may continue to be aneurysmal, often with development of progressive stenosis or occlusion. Myocarditis is a universal feature of acute Kawasaki syndrome, but the occurrence of late abnormalities of myocardial function among children without coronary artery disease is controversial. Aortic and mitral regurgitation may occur in the acute illness, and late-onset valvar regurgitation has been reported as a rare complication. Continued long-term surveillance in patients with and without detected coronary abnormalities is necessary to determine the nature history of Kawasaki syndrome with respect to coronary artery status, myocardial function, and valvar regurgitation.